



THE UNIVERSITY *of* EDINBURGH

Edinburgh Research Explorer

Staphylococcus pseudintermedius Surface Protein L (SpsL) Is Required for Abscess Formation in a Murine Cutaneous Infection Model

Citation for published version:

Richards, A, O'Shea, M, Beard, P, Goncheva, M, Tuffs, S, Fitzgerald, J & Lengeling, A 2018, 'Staphylococcus pseudintermedius Surface Protein L (SpsL) Is Required for Abscess Formation in a Murine Cutaneous Infection Model' *Infection and Immunity*, vol. 86, no. 11, e-00631-18. DOI: 10.1128/IAI.00631-18

Digital Object Identifier (DOI):

[10.1128/IAI.00631-18](https://doi.org/10.1128/IAI.00631-18)

Link:

[Link to publication record in Edinburgh Research Explorer](#)

Document Version:

Publisher's PDF, also known as Version of record

Published In:

Infection and Immunity

Publisher Rights Statement:

This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license.

General rights

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.



1 ***Staphylococcus pseudintermedius* Surface Protein L (SpsL) Is**
2 **Required for Abscess Formation in a Murine Cutaneous Infection**
3 **Model**

4

5

6 Amy C. Richards, Marie O'Shea, Philippa M. Beard*, Mariya I. Goncheva*, Stephen W. Tuffs*, J.
7 Ross Fitzgerald#, Andreas Lengeling*#

8

9 The Roslin Institute, Royal (Dick) School of Veterinary Sciences, University of Edinburgh, UK

10

11

12 Running Title: SpsL is required for Abscess Formation

13

14 Keywords: *Staphylococcus pseudintermedius*, abscess, cellulitis, skin infection

15

16

17

18

19

20

21 #Address correspondence to J. Ross Fitzgerald, ross.fitzgerald@roslin.ed.ac.uk, and Andreas
22 Lengeling, andreas.lengeling@gv.mpg.de

23

24 *Present address: Philippa M. Beard, The Pirbright Institute, Surrey, UK

25 Mariya I. Goncheva, Department of Microbiology and Immunology, Schulich School of Medicine
26 and Dentistry, Western University, London, Ontario, Canada

27 Stephen W. Tuffs, Department of Microbiology and Immunology, Schulich School of Medicine and
28 Dentistry, Western University, London, Ontario, Canada

29 Andreas Lengeling, Max-Planck-Society – Administrative Headquarters, Munich, Germany

30

31

32

33

34

35 **Abstract**

36 *Staphylococcus pseudintermedius* is the leading cause of pyoderma in dogs and is often associated
37 with recurrent skin infections that require prolonged antibiotic therapy. High levels of antibiotic use
38 have led to multidrug resistance including the emergence of epidemic methicillin-resistant clones.
39 Our understanding of the pathogenesis of *S. pseudintermedius* skin infection is very limited and the
40 identification of the key host-pathogen interactions underpinning infection could lead to the design
41 of novel therapeutic or vaccine-based approaches for controlling disease. Here, we employ a novel
42 murine cutaneous infection model of *S. pseudintermedius* and investigate the role of the two cell
43 wall-associated proteins (SpsD and SpsL) in skin disease pathogenesis. Experimental infection with
44 wildtype *S. pseudintermedius* strain ED99, or a gene-deletion derivative deficient in expression of
45 SpsD, led to a focal accumulation of neutrophils and necrotic debris in the dermis and deeper
46 tissues of the skin, characteristic of a classical cutaneous abscess. In contrast, mice infected with
47 mutants deficient in SpsL or both SpsD and SpsL developed larger cutaneous lesions with distinct
48 histopathological features of regionally extensive cellulitis rather than focal abscessation.
49 Furthermore, comparison of the bacterial load in *S. pseudintermedius*-induced cutaneous lesions
50 revealed a significantly increased burden of bacteria in the mice infected with SpsL-deficient
51 mutants. These findings reveal a key role for SpsL in murine skin abscess formation and highlight a
52 novel function for a bacterial surface protein in determining the clinical outcome and pathology of
53 infection caused by a major canine pathogen.

54

55

56

57

58

59

60 **Introduction**

61 *Staphylococcus pseudintermedius*, a coagulase-positive species, is a natural commensal of
62 the skin and mucosal membranes of dogs with healthy carriage rates reported to range from 46% -
63 92% (1). *S. pseudintermedius* is capable of causing a range of opportunistic infections including
64 urinary tract, ear, wound, and surgery-related infections (1). The most clinically important
65 consequence of *S. pseudintermedius* infection is canine pyoderma with approximately 10% of dogs
66 affected worldwide (2). Canine pyoderma is an umbrella term used to describe a range of clinical
67 manifestations, most commonly superficial bacterial folliculitis and atopic dermatitis, which are
68 often treated with antibiotics alongside topical creams and shampoos containing antimicrobial
69 agents such as chlorhexidine (3, 4). The repeated use of antibiotics in patients with recurrent
70 pyoderma is linked to the development of antibiotic resistance and the rapid global spread of
71 methicillin resistant *S. pseudintermedius* (MRSP), with some strains developing resistance to all
72 commonly used antimicrobials in veterinary medicine (5-8). The high prevalence of multidrug
73 resistant *S. pseudintermedius* is a major concern for the continued treatment of canine pyoderma.

74 Our understanding of the pathogenesis of *S. pseudintermedius* infection and the key bacterial
75 factors involved is very limited. Exfoliative toxins ExpA and ExpB, cause intra-epidermal clefts in
76 the skin by directly cleaving canine desmoglein 1 and both intradermal and subcutaneous injection
77 of either exfoliative toxin, in dogs, leads to the development of clinical manifestations of pyoderma
78 including crusting and erythema (9-11). Bacterial adhesins are also thought to be important as the *S.*
79 *pseudintermedius* clinical isolate ED99 demonstrates increased adherence to pyoderma-associated
80 canine corneocytes when compared with healthy corneocytes (12). Of the 18 cell wall-associated
81 (CWA) proteins encoded in the genome sequence of *S. pseudintermedius* clinical isolate ED99, two
82 have been demonstrated to mediate binding to host proteins (13). *S. pseudintermedius* surface
83 proteins D and L (SpsD and SpsL), mediate binding to the host extracellular matrix proteins

84 fibrinogen, fibronectin, and the cytoskeletal protein cytokeratin-10 when expressed by the
85 heterologous host *Lactococcus lactis* (13). Recombinant versions of the SpsD N-terminal A-domain
86 interfere with fibrin clot formation and platelet aggregation *in vitro* and both SpsD and SpsL are
87 sufficient for the invasion of *S. pseudintermedius* into canine progenitor epidermal keratinocytes in
88 a fibronectin-dependent manner *in vitro* (14, 15). To date, the role of *S. pseudintermedius* putative
89 virulence factors have not been examined during experimental infection.

90 Skin infection models have been employed previously to analyse the role of CWA proteins
91 of *Staphylococcus aureus* by subcutaneous injection of wildtype and gene deletion strains (16-18).
92 In these studies, mice develop focal skin abscesses and dermonecrosis within 24 h that subsequently
93 resolve spontaneously after 14 d in the absence of a systemic response (16). These skin lesions can
94 be evaluated using histopathology or homogenised to determine the number of viable bacteria
95 present. Here we develop the first murine infection model of *S. pseudintermedius* and assess the
96 role of SpsD and SpsL in this murine model using single and double deletion strains of *spsD* and
97 *spsL* in the *S. pseudintermedius* clinical isolate ED99, originally isolated in the UK from a dog
98 affected by canine pyoderma (12). We discovered that the wildtype and *spsD*-deficient-infected
99 mice developed classical abscessation near the inoculation site. In contrast, mice inoculated with
100 *spsL*-deficient or *spsLspsD*-deficient strains, developed an alternative clinical pathology described
101 as cellulitis. These findings demonstrate that a bacterial CWA protein determines the clinical
102 outcome of infection in a novel murine cutaneous model.

103

104

105 **Results**

106 **SpsD and SpsL of *S. pseudintermedius* ED99 Adhere to Murine Fibronectin,**
107 **Fibrinogen, and Cytokeratin-10.** Previous work demonstrated that *S. pseudintermedius* SpsD and

108 SpsL can mediate binding to extracellular matrix proteins fibronectin and fibrinogen and the
109 cytoskeletal protein cytokeratin-10, when expressed on the surface of a heterologous host *L. lactis*
110 (2). To determine if murine skin was a suitable model for the analysis of SpsD and SpsL, we
111 examined their capacity to mediate binding to the murine proteins fibronectin, fibrinogen, and
112 cytokeratin-10. The expression of SpsD and SpsL on the surface of *L. lactis* mediated binding to
113 murine fibronectin, fibrinogen, and cytokeratin-10, with SpsD demonstrating stronger binding to
114 murine cytokeratin-10 and fibrinogen than SpsL (Fig. 1A and B). This suggests that the role of
115 SpsD and SpsL in the pathogenesis of *S. pseudintermedius* canine pyoderma can be examined in a
116 murine infection model.

117 In order to examine the importance of SpsD and SpsL in mediating binding of *S.*
118 *pseudintermedius* ED99 to the same murine ligands, we performed solid phase bacterial adherence
119 assays with wildtype, and single or double *spsL* and *spsD* deletion mutants (15). Expression
120 analysis demonstrated that SpsD is expressed on the cell surface at early exponential phase (OD₆₀₀
121 of 0.2) with SpsL expressed on the cell surface throughout the exponential phase (data not shown).
122 Accordingly, the binding potential of CWA SpsD and SpsL were investigated by solid phase
123 adherence assays at early exponential growth phase. As expected, *S. pseudintermedius* ED99
124 demonstrated adherence to murine fibronectin, murine fibrinogen, and murine cytokeratin-10 (Fig.
125 1C-1E). Equivalent murine fibronectin binding to the wildtype was observed for ED99 Δ *spsD*
126 demonstrating that SpsL is promoting binding to fibronectin (Fig. 1C). However, ED99 Δ *spsL*
127 retains a reduced adherence to fibronectin demonstrating that SpsD is sufficient for fibronectin-
128 binding (Fig. 1C). Adherence to murine fibrinogen was reduced in comparison to the other ligands
129 with both ED99 Δ *spsD* and ED99 Δ *spsL* exhibiting reduced binding suggesting that both SpsL and
130 SpsD, respectively, are capable of mediating adherence to murine fibrinogen (Fig. 1D).
131 Surprisingly, ED99 Δ *spsL* exhibits poor binding to cytokeratin-10 suggesting that SpsL is the main
132 mediator of cytokeratin-10 binding (Fig. 1E). Of note, ED99 Δ *spsL* Δ *spsD* demonstrated complete

133 ablation of binding to all three ligands confirming that SpsD and SpsL are the only CWA proteins
134 of *S. pseudintermedius* ED99 promoting adherence to murine fibronectin, fibrinogen, and
135 cytokeratin-10 under these assay conditions (Fig. 1A-C).

136 **Development of a Murine Cutaneous Infection Model of *S. pseudintermedius* ED99.**

137 Initially, pilot experiments were performed to develop the first murine skin infection model of *S.*
138 *pseudintermedius*. Female BALB/c mice received an injection of either 100 μ l volume PBS or
139 1×10^7 CFU of *S. pseudintermedius* ED99 (in 100 μ l PBS) as a bolus into the subcutaneous tissue of
140 the dorsal midline, just caudal to the interscapular region. Mice were then monitored for 4 d post-
141 infection (dpi) to determine the severity of the disease and follow the development of skin lesions.
142 The wildtype-infected mice exhibited a trend towards greater weight loss than the control mice but
143 this was not significant suggesting that a systemic infection did not occur (Fig. 2A), and there were
144 no differences in the size of excised spleens (Fig. S1A). Cutaneous lesions in the wildtype-infected
145 mice became visible on the back or flank of the mouse at 2 dpi and became more prominent by 4
146 dpi (Fig. 2B). The gross pathology was typified by a soft cutaneous lesion of varying shape up to 9
147 mm along the longest axis, unattached to the underlying tissue, and with a well-defined, reddened
148 margin. On the cut surface there were one or 2 circumscribed, round, soft to liquid areas (pus)
149 approximately 1-2 mm diameter within the dermis and subcutis underlying the lesion.

150 A subset of mice were euthanised at 1, 2, and 4 dpi and the dorsal cutaneous tissue excised,
151 fixed in 10 % formal saline and processed using standard procedures to tissue sections which were
152 then stained with haematoxylin and eosin and examined by a veterinary pathologist (P.M.B). No
153 significant pathology was identified in the tissue from the control mice (Fig. 2C). Wildtype-infected
154 mice developed classic skin abscesses characterised by a focal accumulation of neutrophils (some
155 degenerate), cellular debris and bacteria (Fig. 2D), with no appreciable differences in size or disease
156 severity over time (Fig. S1 B and C). This pilot study demonstrated that *S. pseudintermedius*-

157 infected mice develop classic cutaneous abscesses similar to those clinically described in dogs
158 affected by *S. pseudintermedius* pyoderma (3).

159 **Infection with *S. pseudintermedius* Lacking SpsD and SpsL Cell Wall-associated**
160 **Proteins Results in a Distinct Skin Infection Pathology.** The murine *S. pseudintermedius* skin
161 infection model was used to determine the role of bacterial CWA proteins in the pathogenesis of
162 cutaneous infection. Female BALB/c mice were injected subcutaneously as described previously
163 with either *S. pseudintermedius* wildtype or the derivative ED99 Δ spsL Δ spsD deletion mutant and
164 monitored for 3 dpi. The mice infected with the ED99 Δ spsL Δ spsD strain lost more body weight
165 than the mice infected with the wildtype strain at all three time points ($p \leq 0.05$ at 2 dpi) (Fig. 3A).
166 Gross examination of the site of inoculation revealed that the wildtype-infected mice developed
167 raised, soft cutaneous lesions with a reddened margin similar to those described in the pilot
168 experiments above. In comparison, ED99 Δ spsL Δ spsD-infected mice developed flattened,
169 longitudinally extended cutaneous lesions that covered a larger area (Fig. S2). Measurement of the
170 cutaneous lesions along the longest axis confirmed that ED99 Δ spsL Δ spsD-infected mice develop
171 significantly longer lesions than wildtype-infected mice at both 2 and 3 dpi ($p \leq 0.001$) (Fig. 3B).
172 Histopathological examination of the inoculated area in mice infected with the wildtype strain
173 revealed the presence of focal, well circumscribed abscesses consistent with that observed in the
174 pilot study (Fig. 3C). However, focal abscess formation was not observed in the ED99 Δ spsL Δ spsD-
175 infected mice, which instead revealed cellulitis characterised by poorly delineated, regionally
176 extensive areas of suppurative inflammation accompanied by abundant necrotic debris, particularly
177 in the deeper cutaneous layers (Fig. 3C). The inflammatory infiltrate extended laterally between
178 tissue planes. Both distinct pathology types, abscessation and cellulitis, contained neutrophils as the
179 predominant inflammatory cell (Fig. 3C). No differences in spleen length or infection severity
180 between infection groups was recorded with wide within-group variation observed (Fig. S3A and
181 B). The categorisation of cellulitis correlated with larger histopathological lesions in

182 ED99 Δ *spsL* Δ *spsD*-infected mice in comparison to wildtype-infected mice at both 2 ($p \leq 0.05$) and 3
183 dpi ($p \leq 0.0001$) (Fig. 3D). Categorising the histopathological changes into abscessation or cellulitis
184 confirmed decreased abscess formation in ED99 Δ *spsL* Δ *spsD*-infected mice ($p \leq 0.005$) (Fig. 3E).
185 These data suggest that formation of a focal abscess after cutaneous inoculation in mice is
186 dependent on expression of one or more CWA proteins.

187 **SpsL is Required for the Development of Skin Abscesses in a Murine Infection Model.**

188 In order to investigate the relative role of SpsD and SpsL, single gene deletion mutants,
189 ED99 Δ *spsD* and ED99 Δ *spsL*, were employed. Ten female BALB/c mice were inoculated with
190 either wildtype, ED99 Δ *spsD*, ED99 Δ *spsL*, or ED99 Δ *spsL* Δ *spsD* strains of *S. pseudintermedius* as
191 described above, monitored, and euthanized at 1, 2, and 3 dpi. Measurement of body weight and
192 cutaneous lesion length demonstrated that ED99 Δ *spsD*-infected mice displayed characteristics more
193 similar to the wildtype-infected mice, while both the ED99 Δ *spsL*- and ED99 Δ *spsL* Δ *spsD*-infected
194 mice displayed decreased body weight (Fig. 4A), and increased lesion length ($p \leq 0.001$) (Fig 4B) in
195 comparison to wildtype-infected mice. Although upon histopathological examination no differences
196 in histopathology lesion length were identified (Fig. 4C), clear differences were observed in the
197 type of histopathology present between experimental groups (Fig 4D). The wildtype- and
198 ED99 Δ *spsD*-infected mice were more likely to develop abscesses, and the ED99 Δ *spsL*- and
199 ED99 Δ *spsL* Δ *spsD*-infected mice were more likely to develop cellulitis ($p \leq 0.01$) (Fig. 4D).

200 To confirm the role of SpsL in abscess formation and fulfil Molecular Koch's postulates
201 (19), the *spsL* gene was re-introduced to the ED99 Δ *spsL* strain by allele replacement as described in
202 the Materials and Methods. The ED99 Δ *spsL* Repaired (Rep) strain demonstrated restored SpsL
203 surface expression and bacterial adherence to canine fibrinogen allowing analysis in the murine
204 model alongside the wildtype and ED99 Δ *spsL* strain using the same experimental setup as above
205 (Fig. S4). Gross examination identified no differences in the body weight of mice from all
206 experimental groups (Fig. 5A). However, there were raised, soft cutaneous lesions with a reddened

207 margin present at the inoculation site of the ED99 Δ *spsL* Rep-infected mice similar to the wildtype-
208 infected mice with the ED99 Δ *spsL*-infected mice demonstrating flattened, cutaneous lesions that
209 were significantly longer at 1 ($p \leq 0.05$) and 2 dpi ($p \leq 0.001$) (Fig. 5B). Histopathological
210 examination confirmed that ED99 Δ *spsL* Rep-infected mice were more likely to develop abscesses
211 than ED99 Δ *spsL*-infected mice ($p \leq 0.001$) (Fig. 5C). These data indicate that SpsL is the first *S.*
212 *pseudintermedius* virulence factor to be described and that SpsL plays a key role in determining the
213 pathology of *S. pseudintermedius* infection in this murine cutaneous model.

214 **Cellulitis is Linked with Increased Bacterial Load.** In order to quantify the number of
215 viable bacteria associated with the two observed pathology types, the above experiment involving 4
216 experimental groups, was repeated. At 1, 2, and 3 dpi the mice were euthanised, the cutaneous
217 lesion on the dorsal midline excised, homogenised, and cultured to determine the number of live
218 bacteria present in the tissue (total CFU/lesion). The same gross observations were identified
219 relating to larger lesions in ED99 Δ *spsL*- and ED99 Δ *spsL* Δ *spsD*-infected mice in comparison to
220 wildtype- and ED99 Δ *spsD*-infected mice (data not shown). In addition, increased bacterial load was
221 identified in ED99 Δ *spsL*- and ED99 Δ *spsL* Δ *spsD*-infected mice in comparison to wildtype- and
222 ED99 Δ *spsD*-infected mice at 2 and 3 dpi ($p \leq 0.001$) (Fig. 6). Importantly, mice infected with a
223 strain with a restored *spsL* gene, ED99 Δ *spsL* Rep, had less bacteria present in the cutaneous lesion
224 in comparison to ED99 Δ *spsL*-infected mice at 1 ($p \leq 0.05$), 2 ($p \leq 0.001$), and 3 dpi ($p \leq 0.01$) and with
225 similar numbers to wildtype-infected mice (Fig. 5D). These data reveal an association between
226 pathology and bacterial burden that is dependent on SpsL.

227

228

229 **Discussion**

230 The global dissemination of multidrug resistant MRSP strains is making it increasingly
231 difficult to treat canine pyoderma. There are also increasing reports of human-related infections
232 caused by *S. pseudintermedius* and colonisation of veterinary staff (20-22). Similarly to dogs, skin
233 and soft tissue infections, including abscess formation, are the most common form of disease caused
234 by *S. pseudintermedius* in humans (20, 22). However, some more invasive infections have also been
235 reported including bloodstream-infection and cellulitis (20, 23). If much-needed novel therapeutics
236 are to be developed to combat MRSP then a greater understanding of the critical host-pathogen
237 interactions leading to the development of canine pyoderma and human skin and soft tissue
238 infections is required. Here we have established the first murine model of *S. pseudintermedius* skin
239 infection. Subcutaneous injection of *S. pseudintermedius* ED99 led to the development of focal skin
240 abscesses (Fig. 2B) similar to those observed after subcutaneous injection of *S. aureus* (24). We
241 identified that while SpsD is dispensable, SpsL is required for the development of classic *S.*
242 *pseudintermedius* skin abscesses in the murine model.

243 A common feature of *S. aureus* cutaneous infection models is the development of
244 dermonecrosis, depending on the inoculum dose and bacterial strain used (16, 25). *S. aureus*
245 dermonecrosis is dependent on toxins such as the α -toxin and the α -type phenol-soluble modulins,
246 with mice infected with strains deficient in *hla* or *psma* genes unable to develop dermonecrosis (26-
247 28). No dermonecrosis was evident in this study but necrosis was identified that typically involved
248 the epidermis but was also variably associated with underlying cutaneous layers. This necrosis of
249 the epidermis was present in all experimental groups and was not associated with the development
250 of a particular type of pathology. This demonstrates that the development of cellulitis is not linked
251 with changes in the level of epidermal necrosis and that the dermonecrosis discussed in the *S.*
252 *aureus* literature is not akin to the cellulitis phenotype described here.

253 Clinically, abscess formation and cellulitis are distinct phenotypes that can present
254 simultaneously and can be both acute and chronic (24). Abscesses encase the bacteria in a confined
255 location while cellulitis is more likely to affect a larger area of the skin with diffuse infiltrations of

256 neutrophils (29). The development of cellulitis in dogs is rare but cases of *S. pseudintermedius*-
257 mediated cellulitis have been reported with lymphatic damage linked to bacteraemia and toxic
258 shock or necrotising fasciitis (30-32). There is little understanding as to how either an abscess or
259 cellulitis pathology develops but it has been thought that the host immune response has a pivotal
260 role in driving the development of each pathology (29). The work presented here suggests that
261 bacterial surface proteins can determine the pathological outcome of infection.

262 For *S. aureus*-mediated skin abscesses or micro-abscesses, formed after bloodstream
263 infection, a number of bacterial proteins have been implicated in the development of abscesses (33).
264 The secreted coagulase and von Willebrand-binding protein (vWbp) are required for cutaneous
265 abscess formation in both mice and rabbits (34, 35). In addition, a sortase mutant lacking expression
266 of CWA proteins, as well as strains with deletions of particular genes, such as *clfA*, have been
267 employed to demonstrate the role of CWA proteins in the development of skin abscesses (16).
268 However, in contrast to what we observe with SpsL in the current study, loss of expression does not
269 lead to the development of a cellulitis pathology. These data suggest that SpsL exhibits a function
270 not previously observed among other staphylococcal surface proteins.

271 The most abundant extracellular matrix protein in healthy skin is collagen. However, when
272 skin is damaged, such as during subcutaneous inoculation, the initiation of the coagulation cascade
273 leads to platelet activation resulting in high levels of fibrinogen and fibronectin at the inoculation
274 site (36, 37). We postulate that SpsL promotes abscess formation through the development of a
275 fibrinogen- or fibronectin-shield on the bacterial surface that could initiate bacterial aggregation.
276 The importance of bacterial aggregation for the initial stages of skin abscess development has
277 already been reported for *S. aureus* with bacterial aggregates linked to increased bacterial load and
278 bacterial dissemination (38). In *S. aureus*, this aggregation is coagulase-dependent with a lack of
279 aggregation leading to decreased bacterial burden (38). In contrast, SpsL-dependent abscess
280 formation results in a decreased bacterial burden at 2 and 3 dpi in comparison to the alternative
281 cellulitis pathology (Fig. 6). The widespread conservation of the *spsL* gene in *S. pseudintermedius*

282 strains from across the world suggests that *S. pseudintermedius* could favour the development of
283 subcutaneous abscesses rather than cellulitis (7, 13, 39, 40). Experiments performed over a longer
284 period of time could identify if *S. pseudintermedius* were able to persist and avoid clearance in the
285 SpsL-dependent abscesses in comparison to the cellulitis pathology. Additionally, bacterial
286 aggregation could be beneficial to *S. pseudintermedius* in other types of infection and particularly in
287 the initial stages of biofilm formation, which may promote colonisation and persistence on
288 indwelling devices or atopic skin (41, 42).

289 Ideally, the role of SpsL in abscess formation and the mechanism involved could be further
290 examined using a canine infection model. A canine superficial pyoderma model has been developed
291 allowing the application of bacteria onto artificially created skin abrasions (43). This model
292 produces classical clinical signs of pyoderma including the development of pustules and dermatitis
293 that was self-limiting (43). It would be interesting to investigate the role of both SpsD and SpsL in
294 this model as their role in cell invasion *in vivo* could also be established.

295 In conclusion, by developing the first *S. pseudintermedius* murine model, we have been able
296 to examine the role of the 2 CWA proteins of *S. pseudintermedius*, SpsD and SpsL, in the
297 development of cutaneous infections. We have identified that SpsL promotes the development of
298 abscesses and this is the first description of a bacterial CWA protein influencing the type of
299 cutaneous pathology developed during experimental infection. As so little is known about the
300 immune mechanisms responsible for the development of either an abscess or cellulitis pathology,
301 the model developed here could be useful for future investigations into the molecular basis of these
302 clinical manifestations. More work into the *in vivo* function of virulence factors of *S.*
303 *pseudintermedius* is needed if we aim to develop novel therapeutics to combat the increasingly
304 multi-drug resistant clinical strains of *S. pseudintermedius*.

305

306

307 **Materials and Methods**

308 **Ethics Statement.** All murine experiments were carried out under the authority of a UK
309 Home Office Project License (PPL 70/08663) within the terms and conditions of the strict
310 regulations of the UK Home Office Animals (Scientific Procedures) Act 1986 and the code of
311 practice for the housing and care of animals supplied for scientific purposes. In all experiments
312 female BALB/cANCrI (Charles River, hereafter abbreviated as BALB/c) mice aged between 10-12
313 weeks were used. All mice were housed under specific pathogen-free (SPF) conditions at the
314 Biological Research Facility (BRF) for rodents at the Roslin Institute according to hygiene
315 recommendations of Federation of European Laboratory Animal Science Associations (FELASA)
316 guidelines (44, 45). Mice were randomly assigned to individually ventilated home cages after
317 arrival and acclimatised for 1 to 2 weeks in the facility before being used in infection challenge
318 studies. Animals had, throughout maintenance and infection challenge, *ad libitum* access to food
319 and water. Mice were maintained on a standard diet (Teklad Global 18% Protein Rodent Diet), at an
320 average room temperature of 21°C and a 12:12 h light/dark cycle. All study protocols were
321 reviewed by the Roslin Institute (University of Edinburgh) animal services, consisting of the named
322 veterinary surgeon (NVS), the rodent facility director, and a senior research statistician, prior to
323 each experiment. Animals were monitored twice daily to ensure that no animal exceeded agreed
324 euthanasia criteria including a 20% loss of body weight or moderate signs of general illness. Only
325 mild symptoms of generalised illness were noted with slight decreases in weight, some discharge
326 from the eyes, and starring of the fur. No animal required premature euthanasia with all animals
327 humanely euthanized at the end of experimentation by schedule 1 asphyxiation using carbon
328 dioxide (VetTech Solutions). Euthanized animals were then subjected to cervical dislocation to
329 ensure euthanasia.

330 **Solid Phase Adherence Assays.** Solid phase adherence assays were performed as described
331 previously (13). Briefly, murine fibrinogen (Abcam), murine fibronectin (Abcam), or recombinant
332 murine cytokeratin-10 C-terminus (294-570) (purified as described previously (46)) were coated
333 overnight at 4°C in PBS on 96-well MaxiSorp® plates (Nunc). Wells were blocked with 100 µl 8%

334 (w/v) non-fat dried milk (Fluka Analytical) for 2 h at 37°C. *Lactococcus lactis* strains, characterised
335 previously (13), were cultured overnight in M17 broth (Oxoid), washed in PBS and diluted to an
336 OD₆₀₀ of 1.0 in PBS. *S. pseudintermedius* strains, characterised previously (15), were cultured in
337 Brain Heart Infusion broth (Oxoid) until an OD₆₀₀ of 0.6, washed in PBS and diluted to an OD₆₀₀ of
338 1.0 in PBS. Bacteria were applied to the wells in triplicate and incubated for 2 h at 30°C for *L.*
339 *lactis*, or 2 h at 37°C for *S. pseudintermedius*. Bound bacteria were fixed with 100 µl 25% (v/v)
340 formaldehyde (Sigma-Aldrich) for 30 min and then stained with 50 µl 0.5% (w/v) crystal violet
341 (Sigma-Aldrich) for 3 min. Before analysis, 5% (v/v) acetic acid (BDH Lab Supplies) was applied
342 and the plate read using a SynergyTM HT plate reader (BioTek) at a wavelength of 590 nm.

343 **Murine Skin Infection Model.** The bacterial inoculum was produced by culturing *S.*
344 *pseudintermedius* strains to an OD₆₀₀ of 0.6 in Brain Heart Infusion broth (Oxoid). 10 ml of culture
345 was washed and then diluted in PBS to the relevant OD₆₀₀ to provide 10⁷ colony forming units
346 (CFU) per 100 µl. The size of the inoculum used for infection challenge was confirmed by CFU
347 plating for each experiment.

348 The dorsal midline of isoflurane anaesthetised BALB/c mice were shaved using electric
349 clippers 24 h pre-inoculum. Bacteria were injected into the subcutaneous tissue of the dorsal
350 midline just caudal to the intrascapular region of the BALB/c mouse in 100 µl volume using a 26-
351 gauge needle and a 5 mm needle guard to ensure standard injection depths. Mice were caged with 6
352 or less mice per cage with at least 6 mice per experimental group. All animals were monitored for
353 weight, length of observed lesion along the longest axis using callipers, noting the presence or
354 absence of a lump, as well as identifying any clinical signs of illness. Measuring the longest axis of
355 the lesion was deemed the most appropriate measure as the lesions developed were highly irregular
356 in shape meaning that measurement of lesion width was very subjective. Mice were humanely
357 euthanized at 1, 2, 3, or 4 days post-infection (dpi). Spleens and skin lesions were immediately
358 excised and immersed in 10% formal buffered saline (Fisher Scientific) for histopathological
359 analysis. All experiments were repeated at least twice giving the same results.

360 Skin lesions were trimmed and histopathology slides produced by the Pathology Department
361 of the Royal Dick School of Veterinary Studies, University of Edinburgh using routine methods.
362 Histology slides were stained with hematoxylin and eosin (H&E) giving nuclei a blue staining and
363 proteinaceous material a pink staining. Histopathology slides were analysed blind for lesion length
364 along the longest axis using a magnifying glass and callipers, as well as disease severity and
365 categorised depending on the type of pathology present (abscess/cellulitis). This analysis was
366 independently performed by two persons before unblinding. All histopathology slides included for
367 analysis contained the following 5 layers of skin: epidermis, dermis, panniculus, panniculus
368 carnosus muscle, and adventitia. Histopathology slides were removed from the analysis if only
369 superficial layers of the skin were present on the slide.

370 For colony forming units (CFU) determination, after excision of the skin lesion, the area was
371 sliced into equal sections using a scalpel. These skin sections (containing the whole of the skin
372 lesion) were suspended in 1 ml PBS in Lysing Matrix D tubes containing 1.4 mm ceramic spheres
373 (MP Bio). After calculating the weight of the skin lesion, homogenisation of the skin samples were
374 performed by pulsing the samples at 4.0 m/sec twice for 20 s per pulse with a minute break between
375 pulses. Triplicate serial dilutions were produced per homogenate and plated for CFU enumeration.

376 **Histopathology Severity Scoring.** The overall severity of pathology present on the
377 histopathology slide was scored using the following system: grade 0, minimal pathological changes;
378 grade 1, mild inflammatory changes with a mild increase in the number of neutrophils and
379 lymphocytes present in the panniculus and deeper connective tissue layers; grade 2, moderate
380 pathology with formation of either a focal, well-defined abscess in the skin accompanied by
381 inflammation in surrounding tissues or a laterally-oriented cellulitis with a poorly defined
382 accumulation of neutrophils and cell debris extending between the tissue planes; grade 3, marked
383 pathology displaying more extensive pathology with the abscess or cellulitis effacing a larger area
384 of the section and overlying epidermal ulceration often noted; and grade 4, severe pathology with

385 large abscess or cellulitis formation, epidermal ulceration, and disruption of normal tissue
386 architecture.

387 **Generation of ED99 Δ *spsL* Repaired Strain.** Sequence ligase independent cloning was
388 used to clone the full length *spsL* gene, along with 500 bp flanking regions, into the temperature-
389 sensitive allele replacement vector pIMAY as previously described (47, 48). A synonymous
390 mutation was introduced into the N-terminal region of the *spsL* gene to allow identification in
391 comparison to the wildtype (primer sequences are given in Table S1). The pIMAY plasmid
392 containing the mutated *spsL* gene was electro-transformed into the *S. pseudintermedius* ED99 Δ *spsL*
393 background at 28°C with selection on 10 μ g/ml chloramphenicol. Growth at 37°C selected for
394 plasmid integration before plasmid excision at 28°C. The anti-sense *secY* mechanism was found to
395 be non-functional in *S. pseudintermedius* as previously described (15). The generation of the
396 ED99 Δ *spsL* Rep strain was confirmed by PCR and Sanger sequencing as well as Western blot
397 analysis. CWA protein profiles of strains cultured to an OD₆₀₀ of 0.6 in Brain Heart Infusion broth,
398 produced as described previously (15), were probed with 1 μ g/ml anti-SpsL N2N3 IgY and 0.5
399 μ g/ml F(ab')₂ rabbit anti-chicken HRP-conjugated IgG (Bethyl Laboratories).

400 **Statistical Analysis.** Prism 6 (GraphPad) was employed to present data with statistical
401 analysis performed using Minitab 16. The data of each experiment and each time point was
402 analysed separately with data between time points not pooled except to analyse the pathology type
403 data. The Anderson-darling test was used to assess data normality and equal variance. Data
404 transformation was performed if required and analysed using either a 2-sample unpaired t-test or
405 one-way ANOVA analysis with multiple comparisons performed when appropriate. If the data
406 could not be successfully transformed, nonparametric analysis was performed including Kruskal
407 Wallis or Mann-Whitney U test analysis. For analysis of severity grading, ordinal logistic
408 regression was performed with pathology type data being analysed in pairs using Fisher's exact

409 analysis. For data displaying statistical significance: * represents $p \leq 0.05$, ** represents $p \leq 0.01$, and
410 *** represents $p \leq 0.001$.

411

412

413 **Acknowledgements**

414 The authors would like to thank the following members of staff in the Roslin BRF for excellent
415 animal care that was instrumental for this work: Fraser Laing, Darren Smith, Elizabeth Blackford,
416 Christine Marshall, and Dave Davies. We thank Dr. Jane Gebbie and Dr. Amanda Novak for
417 veterinary advice on infection studies and Dr. Helen Brown for advice and help with statistical
418 analysis. We are grateful for funding from Zoetis Animal Health and the Biotechnology and
419 Biological Sciences Research Council (BBSRC). The work was partly supported by the BBSRC
420 Institute Strategic Program Funding (BBS/E/D/20231761, BBS/E/D/20231762, and
421 BBS/E/D/20002173) provided to J. R. F., and A. L. The protein studied is subject of a patent
422 (US9879054B2).

423

424 Author contributions for this study were as follows. Experiments were conceived by: A.L., J.R.F.,
425 A.C.R., and performed and analysed by: A.C.R., M.O., S.W.T., M.I.G., P.M.B. The manuscript was
426 written by A.C.R., P.M.B., A.L., J.R.F, and reviewed by all authors.

427

428 **References**

- 429 1. **Bannoehr J, Guardabassi L.** 2012. *Staphylococcus pseudintermedius* in the dog: taxonomy,
430 diagnostics, ecology, epidemiology and pathogenicity. *Veterinary Dermatology* **23**:119-124.
- 431 2. **Hillier A, Griffin CE.** 2001. The ACVD task force on canine atopic dermatitis (I): incidence and
432 prevalence. *Veterinary Immunology and Immunopathology* **81**:147-151.
- 433 3. **Hillier A, Lloyd DH, Weese JS, Blondeau JM, Boothe D, Breitschwerdt E, Guardabassi L, Papich**
434 **MG, Rankin S, Turnidge JD, Sykes JE.** 2014. Guidelines for the diagnosis and antimicrobial therapy
435 of canine superficial bacterial folliculitis. *Veterinary Dermatology* **25**:163-175.
- 436 4. **Horvath C, Neuber A.** 2007. Management of canine pyoderma. *Companion Animal* **12**:55-64.

- 437 5. **Ruscher C, Lübke-Becker A, Semmler T, Wleklinski C-G, Paasch A, Šoba A, Stamm I, Kopp P, Wieler**
438 **LH, Walther B.** 2010. Widespread rapid emergence of a distinct methicillin- and multidrug-resistant
439 *Staphylococcus pseudintermedius* (MRSP) genetic lineage in Europe. *Veterinary Microbiology*
440 **144**:340-346.
- 441 6. **Moodley A, Damborg P, Nielsen SS.** 2014. Antimicrobial resistance in methicillin susceptible and
442 methicillin resistant *Staphylococcus pseudintermedius* of canine origin: Literature review from 1980
443 to 2013. *Veterinary Microbiology* **171**:337-341.
- 444 7. **McCarthy AJ, Harrison EM, Stanczak-Mrozek K, Leggett B, Waller A, Holmes MA, Lloyd DH,**
445 **Lindsay JA, Loeffler A.** 2015. Genomic insights into the rapid emergence and evolution of MDR in
446 *Staphylococcus pseudintermedius*. *The Journal of Antimicrobial Chemotherapy* **70**:997-1007.
- 447 8. **Hensel N, Zabel S, Hensel P.** 2016. Prior antibacterial drug exposure in dogs with methicillin-resistant
448 *Staphylococcus pseudintermedius* (MRSP) pyoderma. *Veterinary Dermatology* **27**:72-e20.
- 449 9. **Futagawa-Saito K, Makino S, Sunaga F, Kato Y, Sakurai-Komada N, Ba-Thein W, Fukuyasu T.** 2009.
450 Identification of first exfoliative toxin in *Staphylococcus pseudintermedius*. *FEMS Microbiology*
451 *Letters* **301**:176-180.
- 452 10. **Iyori K, Futagawa-Saito K, Hisatsune J, Yamamoto M, Sekiguchi M, Ide K, Son W-G, Olivry T, Sugai**
453 **M, Fukuyasu T, Iwasaki T, Nishifuji K.** 2011. *Staphylococcus pseudintermedius* exfoliative toxin EX1
454 selectively digests canine desmoglein 1 and causes subcorneal clefts in canine epidermis.
455 *Veterinary Dermatology* **22**:319-326.
- 456 11. **Iyori K, Hisatsune J, Kawakami T, Shibata S, Murayama N, Ide K, Nagata M, Fukata T, Iwasaki T,**
457 **Oshima K, Hattori M, Sugai M, Nishifuji K.** 2010. Identification of a novel *Staphylococcus*
458 *pseudintermedius* exfoliative toxin gene and its prevalence in isolates from canines with pyoderma
459 and healthy dogs. *FEMS Microbiology Letters* **312**:169-175.
- 460 12. **Simou C.** 2005. Adherence of *Staphylococcus intermedius* to corneocytes of healthy and atopic
461 dogs: effect of pyoderma, pruritus score, treatment and gender. *Veterinary Dermatology* **16**:352-
462 361.
- 463 13. **Bannoehr J, Ben Zakour NL, Reglinski M, Inglis NF, Prabhakaran S, Fossum E, Smith DG, Wilson GJ,**
464 **Cartwright RA, Haas J, Hook M, van den Broek AH, Thoday KL, Fitzgerald JR.** 2011. Genomic and
465 surface proteomic analysis of the canine pathogen *Staphylococcus pseudintermedius* reveals
466 proteins that mediate adherence to the extracellular matrix. *Infection and Immunity* **79**:3074-3086.
- 467 14. **Pietrocola G, Geoghegan JA, Rindi S, Di Poto A, Missineo A, Consalvi V, Foster TJ, Speziale P.** 2013.
468 Molecular Characterization of the Multiple Interactions of SpsD, a Surface Protein from
469 *Staphylococcus pseudintermedius*, with Host Extracellular Matrix Proteins. *PLoS ONE* **8**:e66901.
- 470 15. **Pietrocola G, Gianotti V, Richards A, Nobile G, Geoghegan JA, Rindi S, Monk IR, Bordt AS, Foster**
471 **TJ, Fitzgerald JR, Speziale P.** 2015. Fibronectin binding proteins SpsD and SpsL both support
472 invasion of canine epithelial cells by *Staphylococcus pseudintermedius*. *Infection and Immunity*
473 **83**:4093-4102.
- 474 16. **Kwecinski J, Jin T, Josefsson E.** 2014. Surface proteins of *Staphylococcus aureus* play an important
475 role in experimental skin infection. *APMIS* **122**:1240-1250.
- 476 17. **Liu Q, Du X, Hong X, Li T, Zheng B, He L, Wang Y, Otto M, Li M.** 2015. Targeting Surface Protein
477 SasX by Active and Passive Vaccination To Reduce *Staphylococcus aureus* Colonization and
478 Infection. *Infection and Immunity* **83**:2168-2174.
- 479 18. **Patel AH, Nowlan P, Weavers ED, Foster T.** 1987. Virulence of protein A-deficient and alpha-toxin-
480 deficient mutants of *Staphylococcus aureus* isolated by allele replacement. *Infection and Immunity*
481 **55**:3103-3110.
- 482 19. **Falkow S.** 1988. Molecular Koch's Postulates Applied to Microbial Pathogenicity. Review of
483 *Infectious Diseases* **10**:274-276.
- 484 20. **Somayaji R, Priyantha MAR, Rubin JE, Church D.** 2016. Human infections due to *Staphylococcus*
485 *pseudintermedius*, an emerging zoonosis of canine origin: report of 24 cases. *Diagnostic*
486 *Microbiology and Infectious Disease* **85**:471-476.
- 487 21. **Feßler AT, Schuenemann R, Kadlec K, Hensel V, Brombach J, Murugaiyan J, Oechtering G,**
488 **Burgener IA, Schwarz S.** 2018. Methicillin-resistant *Staphylococcus aureus* (MRSA) and methicillin-

- 489 resistant *Staphylococcus pseudintermedius* (MRSP) among employees and in the environment of a
490 small animal hospital. *Veterinary Microbiology* **221**:153-158.
- 491 22. **Lee J, Murray A, Bendall R, Gaze W, Zhang L, Vos M.** 2015. Improved Detection of *Staphylococcus*
492 *intermedius* Group in a Routine Diagnostic Laboratory. *Journal of Clinical Microbiology* **53**:961-963.
- 493 23. **Carmen L, Antonio R, Isabel F, Vanesa P-L, Myriam Z, Laura R-R, José RM, Carmen T.** 2017.
494 *Staphylococcus pseudintermedius* Human Infection Cases in Spain: Dog-to-Human Transmission.
495 *Vector-Borne and Zoonotic Diseases* **17**:268-270.
- 496 24. **Kobayashi SD, Malachowa N, DeLeo FR.** 2015. Pathogenesis of *Staphylococcus aureus* Abscesses.
497 *The American Journal of Pathology* **185**:1518-1527.
- 498 25. **Bunce C, Wheeler L, Reed G, Musser J, Barg N.** 1992. Murine model of cutaneous infection with
499 gram-positive cocci. *Infection and Immunity* **60**:2636-2640.
- 500 26. **Kennedy AD, Wardenburg JB, Gardner DJ, Long D, Whitney AR, Braughton KR, Schneewind O,**
501 **DeLeo FR.** 2010. Targeting of Alpha-Hemolysin by Active or Passive Immunization Decreases
502 Severity of USA300 Skin Infection in a Mouse Model. *Journal of Infectious Diseases* **202**:1050-1058.
- 503 27. **Kobayashi SD, Malachowa N, Whitney AR, Braughton KR, Gardner DJ, Long D, Wardenburg JB,**
504 **Schneewind O, Otto M, DeLeo FR.** 2011. Comparative Analysis of USA300 Virulence Determinants
505 in a Rabbit Model of Skin and Soft Tissue Infection. *Journal of Infectious Diseases* **204**:937-941.
- 506 28. **Wang R, Braughton KR, Kretschmer D, Bach T-HL, Queck SY, Li M, Kennedy AD, Dorward DW,**
507 **Klebanoff SJ, Peschel A, DeLeo FR, Otto M.** 2007. Identification of novel cytolytic peptides as key
508 virulence determinants for community-associated MRSA. *Nature Medicine* **13**:1510-1514.
- 509 29. **Bailey E, Kroshinsky D.** 2011. Cellulitis: diagnosis and management. *Dermatologic Therapy* **24**:229-
510 239.
- 511 30. **Girard C, Higgins R.** 1999. *Staphylococcus intermedius* cellulitis and toxic shock in a dog. *The*
512 *Canadian Veterinary Journal* **40**:501-502.
- 513 31. **Weese JS, Poma R, James F, Buenviaje G, Foster R, Slavic D.** 2009. *Staphylococcus*
514 *pseudintermedius* necrotizing fasciitis in a dog. *The Canadian Veterinary Journal* **50**:655-656.
- 515 32. **Mayer MN, Rubin JE.** 2012. Necrotizing fasciitis caused by methicillin-resistant *Staphylococcus*
516 *pseudintermedius* at a previously irradiated site in a dog. *The Canadian Veterinary Journal* **53**:1207-
517 1210.
- 518 33. **Cheng AG, DeDent AC, Schneewind O, Missiakas D.** 2011. A play in four acts: *Staphylococcus*
519 *aureus* abscess formation. *Trends in Microbiology* **19**:225-232.
- 520 34. **Vanassche T, Verhaegen J, Peetermans WE, Van Ryn J, Cheng A, Schneewind O, Hoylaerts MF,**
521 **Verhamme P.** 2011. Inhibition of staphylothrombin by dabigatran reduces *Staphylococcus aureus*
522 virulence. *Journal of Thrombosis and Haemostasis* **9**:2436-2446.
- 523 35. **Malachowa N, Kobayashi SD, Porter AR, Braughton KR, Scott DP, Gardner DJ, Missiakas DM,**
524 **Schneewind O, DeLeo FR.** 2016. Contribution of *Staphylococcus aureus* Coagulases and Clumping
525 Factor A to Abscess Formation in a Rabbit Model of Skin and Soft Tissue Infection. *PLOS ONE*
526 **11**:e0158293.
- 527 36. **Chester D, Brown AC.** 2017. The role of biophysical properties of provisional matrix proteins in
528 wound repair. *Matrix Biology* **60-61**:124-140.
- 529 37. **Rousselle P, Montmasson M, Garnier C.** 2018. Extracellular matrix contribution to skin wound re-
530 epithelialization. *Matrix Biology*
- 531 38. **Loof TG, Goldmann O, Naudin C, Mörgelin M, Neumann Y, Pils MC, Foster SJ, Medina E, Herwald**
532 **H.** 2015. *Staphylococcus aureus*-induced clotting of plasma is an immune evasion mechanism for
533 persistence within the fibrin network. *Microbiology* **161**:621-627.
- 534 39. **Maali Y, Martins-Simões P, Valour F, Bouvard D, Rasigade J-P, Bes M, Haenni M, Ferry T, Laurent**
535 **F, Trouillet-Assant S.** 2016. Pathophysiological Mechanisms of *Staphylococcus Non-aureus* Bone
536 and Joint Infection: Interspecies Homogeneity and Specific Behavior of *S. pseudintermedius*.
537 *Frontiers in Microbiology* **7**.
- 538 40. **Phumthanakorn N, Chanchaithong P, Prapasarakul N.** 2017. Development of a set of multiplex
539 PCRs for detection of genes encoding cell wall-associated proteins in *Staphylococcus*

- 540 *pseudintermedius* isolates from dogs, humans and the environment. Journal of Microbiological
541 Methods **142**:90-95.
- 542 41. **Vanassche T, Peetermans M, Van Aelst LNL, Peetermans WE, Verhaegen J, Missiakas DM,**
543 **Schneewind O, Hoylaerts MF, Verhamme P.** 2013. The role of staphylothrombin-mediated fibrin
544 deposition in catheter-related *Staphylococcus aureus* infections. Journal of Infectious Diseases
545 **208**:92-100.
- 546 42. **Gonzalez T, Biagini Myers JM, Herr AB, Khurana Hershey GK.** 2017. Staphylococcal Biofilms in
547 Atopic Dermatitis. Current Allergy and Asthma Reports **17**:81.
- 548 43. **Bäumer W, Bizikova P, Jacob M, Linder KE.** 2017. Establishing a canine superficial pyoderma
549 model. Journal of Applied Microbiology **122**:331-337.
- 550 44. **Guillen J.** 2012. FELASA Guidelines and Recommendations. Journal of the American Association for
551 Laboratory Animal Science : JAALAS **51**:311-321.
- 552 45. **rodents Fwgorogfmo, rabbits, Mähler M, Berard M, Feinstein R, Gallagher A, Illgen-Wilcke B,**
553 **Pritchett-Corning K, Raspa M.** 2014. FELASA recommendations for the health monitoring of mouse,
554 rat, hamster, guinea pig and rabbit colonies in breeding and experimental units. Laboratory Animals
555 **48**:178-192.
- 556 46. **Walsh EJ, O'Brien LM, Liang X, Hook M, Foster TJ.** 2004. Clumping Factor B, a Fibrinogen-binding
557 MSCRAMM (Microbial Surface Components Recognizing Adhesive Matrix Molecules) Adhesin of
558 *Staphylococcus aureus*, Also Binds to the Tail Region of Type I Cytokeratin 10. Journal of Biological
559 Chemistry **279**:50691-50699.
- 560 47. **Monk IR, Tree JJ, Howden BP, Stinear TP, Foster TJ.** 2015. Complete Bypass of Restriction Systems
561 for Major *Staphylococcus aureus* Lineages. mBio **6**:e00308.
- 562 48. **Li MZ, Elledge SJ.** 2007. Harnessing homologous recombination in vitro to generate recombinant
563 DNA via SLIC. Nat Meth **4**:251-256.

564 **Figure Legends**

565 **FIG 1** SpsD and SpsL promote adherence to murine fibronectin, fibrinogen, and cytokeratin-10.
566 Bacterial solid phase adherence assays of stationary phase (A) *L. lactis* expressing SpsD, and (B) *L.*
567 *lactis* expressing SpsL to murine fibronectin, fibrinogen, and cytokeratin-10. Bacterial solid phase
568 adherence assays of ED99 wildtype (WT) (closed circle), ED99 Δ spsD (open square), ED99 Δ spsL
569 (closed triangle), and ED99 Δ spsL Δ spsD (open triangle) to (C) murine fibronectin, (D) murine
570 fibrinogen, and (E) murine cytokeratin-10 at early exponential growth phase (OD₆₀₀ of 0.2). Each
571 data point represents the mean value from three independent experiments; error bars represent SD.

572

573 **FIG 2** *S. pseudintermedius* ED99-infected mice develop skin abscesses. Monitoring data is shown
574 as (A) percentage change in body weight and (B) surface lesion length (mm) for ED99 wildtype
575 (WT)-infected mice (black circle) and PBS-control mice (open triangle). Each data point represents

576 an individual mouse. Mean scores (horizontal bars) were analysed by two-sample unpaired t-test,
577 * $p \leq 0.05$ and ** $p \leq 0.01$. (C and D) Representative images of H&E-stained skin sections of a PBS-
578 control mouse and a WT-infected mouse at 4 dpi. A hair follicle and all 5 layers of the skin are
579 labelled in the PBS-control section. The WT section contains a large, well circumscribed abscess in
580 the deeper layers of the skin. The abscess is composed of a necrotic centre surrounded by a
581 concentric ring of neutrophils and cellular debris, and accompanied by suppurative dermatitis,
582 panniculitis, myositis, and myofibre degeneration.

583

584 **FIG 3** Infection with *S. pseudintermedius* ED99 deficient in SpsD and SpsL leads to the
585 development of large surface lesions and cellulitis. Monitoring data is shown as (A) percentage
586 change in body weight and (B) surface lesion length (mm) for WT- (black circle) and
587 ED99 Δ spsL Δ spsD-infected mice (open circle). Each data point represents an individual mouse and
588 data are representative of a single replicate of experiments performed twice. Mean scores
589 (horizontal bars) were analysed by two-sample unpaired t-test. (C) Representative images of H&E-
590 stained skin sections of WT-infected or ED99 Δ spsL Δ spsD-infected mice at 3 dpi. The WT-infected
591 mice display a focal abscess. The ED99 Δ spsL Δ spsD-infected mice display a horizontally oriented
592 inflammation throughout the panniculus carnosus muscle layer akin to cellulitis. Magnification (by
593 100x) of the areas indicated by black rectangles demonstrate that regions of inflammation are
594 composed predominantly of degenerate neutrophils admixed with cellular debris, in all
595 experimental groups. (D) Histopathology lesion length (mm). (E) Number of mice demonstrating
596 each pathology type. No abscesses were documented in the ED99 Δ spsL Δ spsD-infected mice and
597 the inflammation present is more longitudinally extended than in WT-infected mice. Fisher's exact
598 analysis demonstrates differences in infection outcome between WT- and ED99 Δ spsL Δ spsD-
599 infected mice. Significant results are represented as * $p \leq 0.05$, ** $p \leq 0.01$ and *** $p \leq 0.001$.

600

601 **FIG 4** *SpsL* is required for *S. pseudintermedius* abscess formation. Monitoring data is shown as (A)
602 percentage change in body weight and (B) surface lesion length (mm) for WT- (filled circle),
603 ED99 Δ *spsL* Δ *spsD*- (open circle), ED99 Δ *spsD*- (filled square), or ED99 Δ *spsL*-infected mice (open
604 square). Each data point represents an individual mouse and data are representative of a single
605 replicate of experiments performed twice. Mean scores (horizontal bars) were analysed by one-way
606 ANOVA. (C) Histopathology lesion length (mm) was analysed by Kruskal-Wallis. (D) The number
607 of mice demonstrating each pathology type. Fisher's exact analysis demonstrates differences in
608 infection outcome between each experimental group compared to every other experimental group.
609 Significant results are represented as * $p \leq 0.05$, ** $p \leq 0.01$ and *** $p \leq 0.001$.

610

611 **FIG 5** Reintroduction of *spsL* to *S. pseudintermedius* restores the abscess phenotype. (A)
612 Percentage change in body weight. Mean scores (horizontal bars) were analysed by one-way
613 ANOVA. (B) Histopathology lesion length (mm). Mean scores were analysed by Kruskal-Wallis.
614 (C) The number of mice demonstrating each pathology type. Fisher's exact analysis demonstrates
615 differences in infection outcome between each experimental group compared to every other
616 experimental group. (D) Log CFU/lesion. Mean values were analysed by one-way ANOVA with
617 Tukey's multiple comparison analysis. Each data point represents an individual mouse with WT-
618 (filled circle), ED99 Δ *spsL*- (open square), or ED99 Δ *spsL* Rep-infected mice (filled triangle).
619 Significant results are represented as * $p \leq 0.05$, ** $p \leq 0.01$, and *** $p \leq 0.001$.

620

621 **FIG 6** The cellulitis pathology induced by *S. pseudintermedius* deficient in *SpsL* is associated with
622 increased bacterial numbers. The number of CFU were analysed after homogenisation of the
623 excised and trimmed skin lesion. The logged CFU/lesion data is plotted with each data point
624 representing an individual mouse for WT- (filled circle), ED99 Δ *spsL* Δ *spsD*- (open circle),

625 ED99 Δ *spsD*- (filled square), or ED99 Δ *spsL*-infected mice (open square). Mean values (horizontal
 626 bar) were analysed by one-way ANOVA with Tukey's multiple comparison analysis, ** $p \leq 0.01$, and
 627 *** $p \leq 0.001$. Mice infected with bacterial strains lacking the *spsL* gene have increased bacterial
 628 burdens at 2 and 3 dpi.

629


630

631

632

633

634

635 **FIG 1**

636

637

638

639

640

641

642


643

644

645

646

647

648 **FIG 2**

649

650

651

652

653


654

655


656



657

658




659





660

661 **FIG 4**



662

663

664

665


666

667

668

669

670 FIG 5



671

672

673

674

675

676

677

678

679 **FIG 6**

680

681

682

